Compared efficacy of esmolol and amiodarone for controlling New-Onset Atrial Fibrillation in Critical care patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200066158

Enrollment

Unknown

Registered

2022-11-25

Start date

2022-12-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

New-Onset Atrial Fibrillation in Critical care patients

Interventions

Control group:Esmolol

Treatment group :Amiodrone

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with age more than 18 and less than 80 years old; 2. Patients admitted to ICU showed acute atrial fibrillation =120 beats/min; 3. ICU stay for 7 days or more; 4. After obtaining written informed consent from one of the patients/guardians.

Exclusion criteria

Exclusion criteria: 1. VR>200 beats/min; pre-excitation syndrome; a serious heart condition; 2. Severe lung disease, shock, liver or kidney dysfunction, stroke or embolism within 6 months; 3. Allergy or contraindication to the study medications; use of antiarrhythmic and/or atrioventricular nodal blocking drug within last 7 days (in case of amiodarone, within past 3 months); Cardioversion; Confirmed or suspected hyperthyroidism; the presence of implanted pacemaker and/or implantable cardioverter defibrillator

Design outcomes

Primary

Measure	Time frame
heart rate;BNP;Blood pressure;IVC;	—

Countries

China

Contacts

Public ContactJing Cao

First Hospital of Shanxi Medical University

13834691242@163.com+86 138 3469 1242

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026